Embecta (NASDAQ:EMBC) Hits New 12-Month Low at $10.09

Embecta Corp. (NASDAQ:EMBC)’s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.09 and last traded at $10.16, with a volume of 52977 shares traded. The stock had previously closed at $10.25.

Embecta Trading Down 2.3 %

The firm has a market capitalization of $595.95 million, a P/E ratio of 10.89 and a beta of 0.73. The company has a 50-day moving average of $13.67 and a 200-day moving average of $15.67.

Embecta (NASDAQ:EMBC) last announced its earnings results on Friday, February 9th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.15. The business had revenue of $277.30 million during the quarter, compared to analyst estimates of $264.92 million. Embecta had a negative return on equity of 18.66% and a net margin of 4.93%. Embecta’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the company earned $0.93 EPS. Research analysts predict that Embecta Corp. will post 2.14 EPS for the current year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Wednesday, February 28th were issued a dividend of $0.15 per share. The ex-dividend date was Tuesday, February 27th. This represents a $0.60 dividend on an annualized basis and a yield of 5.80%. Embecta’s payout ratio is currently 63.16%.

Insiders Place Their Bets

In other Embecta news, Director David F. Melcher purchased 2,000 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was purchased at an average cost of $16.25 per share, for a total transaction of $32,500.00. Following the acquisition, the director now owns 45,080 shares in the company, valued at approximately $732,550. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.28% of the company’s stock.

Institutional Trading of Embecta

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. bought a new position in Embecta in the 3rd quarter valued at about $197,911,000. River Road Asset Management LLC bought a new position in Embecta in the 3rd quarter valued at about $39,333,000. State Street Corp bought a new position in Embecta in the 3rd quarter valued at about $68,114,000. Krensavage Asset Management LLC bought a new position in Embecta in the 1st quarter valued at about $29,867,000. Finally, Bank of New York Mellon Corp bought a new position in Embecta in the 3rd quarter valued at about $29,545,000. 93.83% of the stock is currently owned by institutional investors and hedge funds.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.